'Drug administration declines to approve Gonoshasthaya Kendra kit'

Gonoshasthaya Kendra said that the Directorate General of Drug Administration (DGDA) did not approve its rapid antibody testing kit.

Gonoshasthaya Kendra made the disclosure in a press statement on Thursday night.

"The DGDA did not accept the recommendations of the BSMMU and refused to grant licence for our GR COVID-19 Rapid Antibody DOT Test kit," reads the statement.

It said the Gonoshasthaya Kendra authorities will shortly make its next steps known.

Earlier, a performance committee led by professor Shahina Tabassum at Bangabandhu Sheikh Mujib Medical University Hospital (BSMMU) tested the efficacy of the kit and said the COVID-19 Rapid Antibody DOT Test kit, developed by the Gonoshasthaya Kendra, is not effective to detect the novel coronavirus infection.